 Norwood, MA, May 19, 2021 GLOBE NEWSWIRE -- Corbus Pharmaceuticals H o ldings, Inc. NASDAQ: CRBP Corbus or the Company, a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced that it has adjourned its 2021 Annual Meeting of Stockholders the Annual Meeting in order to provide stockholders additional time within which to vote on all proposals, including Proposal 4 to approve an amendment to the Companys certificate of incorporation to increase the Companys authorized shares of common stock from 150,000,000 to 300,000,000. 